Progress through the cell cycle appears to be regulated by a number of cyclin-dependent protein kinases, the CdKs. The p16 protein is an inhibitor of CdK 4, encoded by a gene (multiple tumour-suppressor 1, MTS 1, CDKN2 or p16 gene) localised on chromosome 9p2l (Serrano et al., 1993; Kamb et al., 1994; Nobori et al., 1994) . By binding to and inhibiting CdK 4, p16 could suppress cell division in a similar fashion to p21, whose synthesis is stimulated by p53 and which inhibits other CdKs (Pines, 1994) . The p16 gene is therefore considered as a potential tumour-suppressor gene (Serrano et al., 1993; Kamb et al., 1994; Nobori et al., 1994) .
Deletion and loss of heterozygosity of 9p21 is seen in a large variety of tumours, including malignant melanoma, glioma, lung cancer, bladder, pancreatic and renal cancer and acute lymphoblastic leukaemia, and homozygous deletion of the p16 gene has recently been found in 30-85% of cell lines established from those tumours (Caldas et al., 1994; Kamb et al., 1994; Nobori et al., 1994; Quesnel et al., 1995) . Furthermore, melanoma and pancreatic cell lines frequently carry nonsense, missense or frameshift mutations of the p16 gene, predominantly in exon 2 (Kamb et al., 1994) . However, in fresh solid tumours the incidence of homozygous deletion of the p16 gene seems to be lower (10-20%), and point mutations very rare except in melanoma, pancreatic carcinoma and oesophageal carcinoma (Caldas et al., 1994; Mori et al., 1994; Spruck et al., 1994) . Germline p16 mutations may also be associated with familial melanoma (Hussussian et al., 1994) .
Although loss of heterozygosity in the 9p region appears to be quite rare in breast carcinoma, homozygous deletion of the p16 gene was observed in six of ten and two of five breast carcinoma cell lines in two studies (Kamb et al., 1994; Xu et al., 1994 Xu et al. (1994) . Analysis of p16 alterations in a larger number of ER-negative breast carcinomas (i.e. high-risk patients) is therefore required before any conclusion can be made. Finally, some oesophageal, liver, lung and colon cancer cell lines with normal p16 gene coding sequence but absent p16 protein have recently been reported (Okamoto et al., 1994) , and analysis of p16 protein expression will also have to be made in breast carcinoma.
